| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Kidney Injury | 48 | 2023 | 739 | 11.790 |
Why?
|
| Renal Insufficiency, Chronic | 31 | 2023 | 787 | 5.240 |
Why?
|
| Glomerular Filtration Rate | 26 | 2023 | 602 | 2.900 |
Why?
|
| Alberta | 37 | 2023 | 65 | 2.620 |
Why?
|
| Coronary Angiography | 7 | 2022 | 598 | 2.200 |
Why?
|
| Contrast Media | 8 | 2022 | 1472 | 2.190 |
Why?
|
| Percutaneous Coronary Intervention | 6 | 2022 | 342 | 2.160 |
Why?
|
| Kidney Failure, Chronic | 16 | 2022 | 960 | 1.920 |
Why?
|
| Risk Assessment | 25 | 2022 | 6869 | 1.850 |
Why?
|
| Decision Support Systems, Clinical | 3 | 2022 | 252 | 1.840 |
Why?
|
| Renal Dialysis | 19 | 2022 | 945 | 1.690 |
Why?
|
| Renal Replacement Therapy | 8 | 2022 | 135 | 1.670 |
Why?
|
| Acute Coronary Syndrome | 5 | 2020 | 259 | 1.570 |
Why?
|
| Cardiac Catheterization | 6 | 2019 | 687 | 1.570 |
Why?
|
| Nephrology | 5 | 2022 | 151 | 1.400 |
Why?
|
| Kidney Diseases | 9 | 2018 | 691 | 1.390 |
Why?
|
| Postoperative Complications | 8 | 2021 | 5542 | 1.220 |
Why?
|
| Surgical Procedures, Operative | 3 | 2021 | 383 | 1.160 |
Why?
|
| Creatinine | 14 | 2023 | 531 | 1.110 |
Why?
|
| Kidney | 12 | 2023 | 2146 | 1.110 |
Why?
|
| Practice Guidelines as Topic | 7 | 2021 | 2403 | 1.110 |
Why?
|
| Hospitalization | 17 | 2020 | 2083 | 1.030 |
Why?
|
| Electronic Health Records | 3 | 2020 | 929 | 1.030 |
Why?
|
| Cardiovascular Diseases | 10 | 2022 | 2195 | 0.960 |
Why?
|
| Proteinuria | 6 | 2018 | 155 | 0.870 |
Why?
|
| Nurse Practitioners | 1 | 2023 | 63 | 0.870 |
Why?
|
| Cohort Studies | 30 | 2023 | 9244 | 0.860 |
Why?
|
| Risk Factors | 32 | 2022 | 17523 | 0.850 |
Why?
|
| Cause of Death | 6 | 2020 | 752 | 0.840 |
Why?
|
| Feedback | 1 | 2022 | 198 | 0.810 |
Why?
|
| Medical Audit | 1 | 2022 | 188 | 0.810 |
Why?
|
| Cardiac Surgical Procedures | 4 | 2020 | 1237 | 0.810 |
Why?
|
| Ileostomy | 1 | 2021 | 46 | 0.790 |
Why?
|
| Matched-Pair Analysis | 1 | 2021 | 103 | 0.770 |
Why?
|
| Humans | 111 | 2023 | 261506 | 0.730 |
Why?
|
| Diuretics | 1 | 2021 | 170 | 0.720 |
Why?
|
| Models, Biological | 3 | 2019 | 3254 | 0.720 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2021 | 521 | 0.720 |
Why?
|
| Angina Pectoris | 2 | 2016 | 80 | 0.700 |
Why?
|
| Male | 72 | 2023 | 123000 | 0.670 |
Why?
|
| Aged | 58 | 2023 | 70117 | 0.660 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2023 | 257 | 0.650 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2023 | 849 | 0.630 |
Why?
|
| Female | 73 | 2023 | 141928 | 0.630 |
Why?
|
| Arteriovenous Shunt, Surgical | 5 | 2017 | 112 | 0.610 |
Why?
|
| Middle Aged | 58 | 2023 | 86204 | 0.610 |
Why?
|
| Radiography, Interventional | 1 | 2019 | 305 | 0.600 |
Why?
|
| Coronary Artery Disease | 4 | 2022 | 1011 | 0.600 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2020 | 343 | 0.600 |
Why?
|
| Aftercare | 2 | 2023 | 259 | 0.600 |
Why?
|
| Aged, 80 and over | 33 | 2022 | 29902 | 0.590 |
Why?
|
| Continuous Positive Airway Pressure | 2 | 2015 | 80 | 0.590 |
Why?
|
| Urination | 1 | 2016 | 36 | 0.580 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 1945 | 0.570 |
Why?
|
| Incidence | 14 | 2022 | 5673 | 0.570 |
Why?
|
| Quality Indicators, Health Care | 2 | 2018 | 348 | 0.550 |
Why?
|
| Mortality | 6 | 2021 | 343 | 0.550 |
Why?
|
| Models, Theoretical | 3 | 2019 | 785 | 0.540 |
Why?
|
| Diabetes Mellitus | 4 | 2022 | 1054 | 0.520 |
Why?
|
| Mandibular Advancement | 1 | 2014 | 2 | 0.520 |
Why?
|
| Comorbidity | 9 | 2018 | 2352 | 0.520 |
Why?
|
| Decision Support Techniques | 2 | 2019 | 622 | 0.510 |
Why?
|
| Disease Progression | 11 | 2022 | 6682 | 0.500 |
Why?
|
| Albuminuria | 5 | 2019 | 113 | 0.490 |
Why?
|
| Peptide Fragments | 1 | 2020 | 1271 | 0.490 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2019 | 314 | 0.490 |
Why?
|
| Disease Management | 1 | 2020 | 1052 | 0.480 |
Why?
|
| Communication | 1 | 2020 | 876 | 0.480 |
Why?
|
| Angiotensin Receptor Antagonists | 4 | 2021 | 151 | 0.460 |
Why?
|
| Catheterization, Central Venous | 3 | 2017 | 354 | 0.460 |
Why?
|
| Prognosis | 17 | 2021 | 21713 | 0.460 |
Why?
|
| Polyuria | 1 | 2013 | 13 | 0.460 |
Why?
|
| Arthritis, Reactive | 1 | 2013 | 10 | 0.460 |
Why?
|
| Aortic Valve Stenosis | 1 | 2019 | 476 | 0.460 |
Why?
|
| Renal Artery Obstruction | 1 | 2013 | 38 | 0.450 |
Why?
|
| Vertebral Artery | 1 | 2013 | 42 | 0.450 |
Why?
|
| Carotid Artery Injuries | 1 | 2013 | 40 | 0.450 |
Why?
|
| Kidney Transplantation | 1 | 2019 | 755 | 0.440 |
Why?
|
| Cerebral Angiography | 1 | 2013 | 129 | 0.440 |
Why?
|
| Coronary Artery Bypass | 3 | 2016 | 708 | 0.430 |
Why?
|
| Veterans Health | 1 | 2014 | 181 | 0.420 |
Why?
|
| Myocardial Infarction | 4 | 2020 | 1374 | 0.420 |
Why?
|
| Hyponatremia | 1 | 2013 | 82 | 0.420 |
Why?
|
| Patient Admission | 3 | 2020 | 220 | 0.410 |
Why?
|
| Critical Care | 2 | 2020 | 770 | 0.410 |
Why?
|
| Canada | 10 | 2020 | 429 | 0.400 |
Why?
|
| Ischemic Attack, Transient | 3 | 2023 | 55 | 0.400 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2013 | 176 | 0.400 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2014 | 228 | 0.380 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 918 | 0.380 |
Why?
|
| Hypertension | 3 | 2015 | 1503 | 0.380 |
Why?
|
| Intensive Care Units | 5 | 2020 | 717 | 0.370 |
Why?
|
| Severity of Illness Index | 11 | 2020 | 4320 | 0.360 |
Why?
|
| Qualitative Research | 3 | 2023 | 556 | 0.350 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2017 | 1303 | 0.350 |
Why?
|
| Kidney Function Tests | 6 | 2021 | 192 | 0.350 |
Why?
|
| Atrial Fibrillation | 3 | 2023 | 719 | 0.350 |
Why?
|
| Retrospective Studies | 29 | 2023 | 37905 | 0.340 |
Why?
|
| Length of Stay | 4 | 2020 | 1900 | 0.320 |
Why?
|
| Health Care Costs | 4 | 2017 | 674 | 0.320 |
Why?
|
| Quality Assurance, Health Care | 1 | 2013 | 585 | 0.320 |
Why?
|
| Quality of Life | 3 | 2018 | 4532 | 0.320 |
Why?
|
| Adult | 33 | 2023 | 77950 | 0.310 |
Why?
|
| Propensity Score | 4 | 2021 | 750 | 0.310 |
Why?
|
| Societies, Medical | 2 | 2018 | 1335 | 0.310 |
Why?
|
| Observational Studies as Topic | 2 | 2021 | 140 | 0.310 |
Why?
|
| Conservative Treatment | 2 | 2018 | 58 | 0.300 |
Why?
|
| Time Factors | 16 | 2020 | 12926 | 0.300 |
Why?
|
| Case-Control Studies | 3 | 2021 | 6100 | 0.290 |
Why?
|
| Sick Leave | 2 | 2023 | 6 | 0.290 |
Why?
|
| Rural Health Services | 2 | 2017 | 39 | 0.280 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2008 | 181 | 0.280 |
Why?
|
| Odds Ratio | 5 | 2021 | 2316 | 0.270 |
Why?
|
| Treatment Outcome | 16 | 2020 | 32848 | 0.260 |
Why?
|
| Catheters, Indwelling | 1 | 2008 | 374 | 0.260 |
Why?
|
| Depression | 1 | 2014 | 1715 | 0.250 |
Why?
|
| Fibrosis | 2 | 2018 | 793 | 0.240 |
Why?
|
| Nephrologists | 1 | 2023 | 13 | 0.240 |
Why?
|
| Fee-for-Service Plans | 1 | 2023 | 40 | 0.230 |
Why?
|
| Hospitals | 3 | 2023 | 485 | 0.230 |
Why?
|
| Global Health | 3 | 2018 | 657 | 0.220 |
Why?
|
| Focus Groups | 2 | 2020 | 256 | 0.220 |
Why?
|
| Vascular Access Devices | 2 | 2013 | 51 | 0.220 |
Why?
|
| Insulins | 1 | 2022 | 18 | 0.220 |
Why?
|
| Caregivers | 2 | 2019 | 677 | 0.220 |
Why?
|
| Stroke | 3 | 2023 | 1144 | 0.220 |
Why?
|
| Predictive Value of Tests | 7 | 2019 | 4892 | 0.210 |
Why?
|
| Cardiac Rehabilitation | 1 | 2022 | 23 | 0.210 |
Why?
|
| Bacteremia | 1 | 2008 | 689 | 0.210 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2023 | 108 | 0.200 |
Why?
|
| Medical Overuse | 1 | 2021 | 45 | 0.200 |
Why?
|
| Hypoglycemia | 1 | 2022 | 213 | 0.200 |
Why?
|
| Selection Bias | 1 | 2021 | 50 | 0.190 |
Why?
|
| Acute Disease | 2 | 2019 | 2422 | 0.190 |
Why?
|
| Nitrogen Dioxide | 1 | 2020 | 17 | 0.190 |
Why?
|
| Brain Ischemia | 1 | 2023 | 292 | 0.190 |
Why?
|
| Population Dynamics | 1 | 2020 | 42 | 0.190 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 2992 | 0.190 |
Why?
|
| Warfarin | 2 | 2023 | 152 | 0.190 |
Why?
|
| Renal Insufficiency | 2 | 2021 | 321 | 0.180 |
Why?
|
| Peritoneal Dialysis | 1 | 2022 | 125 | 0.180 |
Why?
|
| Health Personnel | 2 | 2023 | 625 | 0.180 |
Why?
|
| Bias | 1 | 2021 | 205 | 0.180 |
Why?
|
| Perioperative Care | 2 | 2021 | 451 | 0.180 |
Why?
|
| Survival Analysis | 5 | 2020 | 9180 | 0.180 |
Why?
|
| Organ Dysfunction Scores | 1 | 2019 | 66 | 0.180 |
Why?
|
| Air Pollution | 1 | 2020 | 87 | 0.170 |
Why?
|
| Follow-Up Studies | 10 | 2018 | 14889 | 0.170 |
Why?
|
| Referral and Consultation | 3 | 2022 | 899 | 0.170 |
Why?
|
| Intraoperative Period | 1 | 2019 | 246 | 0.170 |
Why?
|
| Interviews as Topic | 1 | 2020 | 497 | 0.170 |
Why?
|
| Coronary Disease | 2 | 2014 | 764 | 0.170 |
Why?
|
| Aminobutyrates | 1 | 2018 | 16 | 0.170 |
Why?
|
| Valsartan | 1 | 2018 | 38 | 0.170 |
Why?
|
| Neprilysin | 1 | 2018 | 66 | 0.170 |
Why?
|
| Age Factors | 5 | 2021 | 5377 | 0.160 |
Why?
|
| Forecasting | 1 | 2021 | 694 | 0.160 |
Why?
|
| Hospital Costs | 1 | 2020 | 228 | 0.160 |
Why?
|
| Registries | 4 | 2019 | 2170 | 0.160 |
Why?
|
| Environmental Exposure | 1 | 2020 | 288 | 0.160 |
Why?
|
| Tetrazoles | 1 | 2018 | 106 | 0.160 |
Why?
|
| Patient-Centered Care | 1 | 2021 | 294 | 0.160 |
Why?
|
| Curcumin | 1 | 2018 | 117 | 0.160 |
Why?
|
| Heart Failure | 4 | 2017 | 2516 | 0.160 |
Why?
|
| Self-Management | 1 | 2019 | 89 | 0.160 |
Why?
|
| Colonic Polyps | 1 | 2020 | 209 | 0.150 |
Why?
|
| Health Services, Indigenous | 1 | 2017 | 5 | 0.150 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 4988 | 0.150 |
Why?
|
| Physicians | 2 | 2023 | 882 | 0.150 |
Why?
|
| Shock, Cardiogenic | 1 | 2019 | 228 | 0.150 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2020 | 340 | 0.150 |
Why?
|
| Primary Health Care | 1 | 2023 | 787 | 0.150 |
Why?
|
| Biphenyl Compounds | 1 | 2018 | 194 | 0.150 |
Why?
|
| Gadolinium | 1 | 2018 | 164 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 7551 | 0.150 |
Why?
|
| Indians, North American | 1 | 2017 | 87 | 0.150 |
Why?
|
| Health Services Needs and Demand | 1 | 2019 | 244 | 0.150 |
Why?
|
| Pyrenes | 1 | 2016 | 9 | 0.150 |
Why?
|
| Patient Participation | 1 | 2020 | 446 | 0.140 |
Why?
|
| Drug Combinations | 1 | 2018 | 621 | 0.140 |
Why?
|
| Elective Surgical Procedures | 2 | 2018 | 250 | 0.140 |
Why?
|
| Medicine | 1 | 2018 | 137 | 0.140 |
Why?
|
| Health Status | 2 | 2018 | 590 | 0.140 |
Why?
|
| Colonoscopy | 1 | 2020 | 518 | 0.140 |
Why?
|
| Health Resources | 1 | 2017 | 168 | 0.140 |
Why?
|
| Urban Health Services | 1 | 2016 | 37 | 0.140 |
Why?
|
| Hospital Mortality | 4 | 2020 | 1274 | 0.140 |
Why?
|
| Anticoagulants | 2 | 2023 | 787 | 0.130 |
Why?
|
| Risk | 3 | 2019 | 1972 | 0.130 |
Why?
|
| Vitamin D Deficiency | 1 | 2016 | 115 | 0.130 |
Why?
|
| Income | 1 | 2016 | 222 | 0.130 |
Why?
|
| Catheterization | 1 | 2017 | 410 | 0.130 |
Why?
|
| Patient Selection | 2 | 2014 | 2055 | 0.130 |
Why?
|
| Surveys and Questionnaires | 2 | 2018 | 5687 | 0.130 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2015 | 82 | 0.130 |
Why?
|
| Aortic Valve | 1 | 2019 | 581 | 0.120 |
Why?
|
| Physician-Patient Relations | 1 | 2020 | 792 | 0.120 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2018 | 384 | 0.120 |
Why?
|
| Vitamin D | 1 | 2016 | 261 | 0.120 |
Why?
|
| Meta-Analysis as Topic | 1 | 2015 | 276 | 0.120 |
Why?
|
| Image Enhancement | 1 | 2018 | 561 | 0.120 |
Why?
|
| Survivors | 2 | 2023 | 1031 | 0.120 |
Why?
|
| Patient Discharge | 2 | 2023 | 661 | 0.120 |
Why?
|
| Catheter-Related Infections | 2 | 2017 | 270 | 0.120 |
Why?
|
| Databases, Factual | 4 | 2020 | 2218 | 0.120 |
Why?
|
| Pneumothorax | 1 | 2015 | 153 | 0.120 |
Why?
|
| Quality Improvement | 1 | 2020 | 851 | 0.110 |
Why?
|
| Research Design | 1 | 2021 | 1544 | 0.110 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2013 | 76 | 0.110 |
Why?
|
| Residence Characteristics | 1 | 2016 | 348 | 0.110 |
Why?
|
| Publication Bias | 1 | 2013 | 38 | 0.110 |
Why?
|
| Aging | 1 | 2021 | 1582 | 0.110 |
Why?
|
| Hypoxia | 1 | 2015 | 443 | 0.110 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 748 | 0.110 |
Why?
|
| Chronic Disease | 4 | 2023 | 1819 | 0.110 |
Why?
|
| Patient Care Team | 1 | 2017 | 795 | 0.100 |
Why?
|
| Cost of Illness | 1 | 2015 | 498 | 0.100 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 6009 | 0.100 |
Why?
|
| Hepatectomy | 1 | 2018 | 1011 | 0.100 |
Why?
|
| Diabetic Angiopathies | 1 | 2012 | 78 | 0.100 |
Why?
|
| Cancer Survivors | 1 | 2018 | 650 | 0.100 |
Why?
|
| Oxygen | 1 | 2015 | 754 | 0.100 |
Why?
|
| Poisson Distribution | 1 | 2010 | 91 | 0.100 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 482 | 0.090 |
Why?
|
| Creatine | 1 | 2010 | 61 | 0.090 |
Why?
|
| Fractures, Bone | 1 | 2013 | 291 | 0.090 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2017 | 705 | 0.090 |
Why?
|
| Delphi Technique | 2 | 2022 | 210 | 0.090 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 598 | 0.090 |
Why?
|
| Information Services | 1 | 2009 | 50 | 0.090 |
Why?
|
| Lymphoma | 1 | 2018 | 1467 | 0.090 |
Why?
|
| Radiography | 1 | 2014 | 1904 | 0.090 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 1085 | 0.090 |
Why?
|
| Cholesterol, LDL | 1 | 2013 | 565 | 0.090 |
Why?
|
| Ascorbic Acid | 1 | 2009 | 131 | 0.080 |
Why?
|
| Young Adult | 4 | 2021 | 21445 | 0.080 |
Why?
|
| Hyperlipidemias | 1 | 2011 | 235 | 0.080 |
Why?
|
| Delivery of Health Care | 1 | 2016 | 860 | 0.080 |
Why?
|
| Mass Screening | 1 | 2017 | 1509 | 0.080 |
Why?
|
| Recovery of Function | 3 | 2017 | 703 | 0.080 |
Why?
|
| Administration, Topical | 1 | 2008 | 257 | 0.080 |
Why?
|
| Lupus Nephritis | 1 | 2007 | 48 | 0.070 |
Why?
|
| Mycophenolic Acid | 1 | 2007 | 148 | 0.070 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2018 | 2027 | 0.070 |
Why?
|
| Hemorrhage | 2 | 2023 | 712 | 0.070 |
Why?
|
| Logistic Models | 3 | 2020 | 3441 | 0.070 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2008 | 418 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 4971 | 0.060 |
Why?
|
| Drug Prescriptions | 2 | 2018 | 289 | 0.060 |
Why?
|
| Biomarkers | 4 | 2018 | 5047 | 0.060 |
Why?
|
| Adolescent | 2 | 2021 | 31252 | 0.060 |
Why?
|
| Anemia | 1 | 2009 | 689 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 4744 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2013 | 12873 | 0.060 |
Why?
|
| Hypovolemia | 1 | 2022 | 12 | 0.060 |
Why?
|
| Obesity | 1 | 2015 | 2884 | 0.060 |
Why?
|
| Pharmacists | 1 | 2023 | 95 | 0.050 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2022 | 108 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2017 | 945 | 0.050 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 4557 | 0.050 |
Why?
|
| Hemoglobins | 2 | 2016 | 477 | 0.050 |
Why?
|
| Critical Illness | 2 | 2019 | 714 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2007 | 1375 | 0.050 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2020 | 22 | 0.050 |
Why?
|
| Exercise Test | 1 | 2022 | 312 | 0.050 |
Why?
|
| Health Planning | 1 | 2020 | 26 | 0.050 |
Why?
|
| Critical Pathways | 1 | 2021 | 149 | 0.050 |
Why?
|
| Environmental Monitoring | 1 | 2020 | 105 | 0.050 |
Why?
|
| Patient Preference | 1 | 2022 | 218 | 0.040 |
Why?
|
| APACHE | 1 | 2019 | 93 | 0.040 |
Why?
|
| Long-Term Care | 1 | 2020 | 83 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 460 | 0.040 |
Why?
|
| Natriuretic Peptide, C-Type | 1 | 2018 | 16 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2018 | 63 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 978 | 0.040 |
Why?
|
| Interleukin-18 | 1 | 2018 | 100 | 0.040 |
Why?
|
| Survival Rate | 3 | 2018 | 12221 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 543 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2022 | 1244 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2019 | 700 | 0.040 |
Why?
|
| Administrative Claims, Healthcare | 1 | 2017 | 10 | 0.040 |
Why?
|
| Australasia | 1 | 2017 | 5 | 0.040 |
Why?
|
| Catheter Obstruction | 1 | 2017 | 8 | 0.040 |
Why?
|
| Manitoba | 1 | 2017 | 4 | 0.040 |
Why?
|
| Motor Vehicles | 1 | 2017 | 8 | 0.040 |
Why?
|
| Aviation | 1 | 2017 | 10 | 0.040 |
Why?
|
| Prevalence | 2 | 2017 | 3260 | 0.040 |
Why?
|
| Point-of-Care Testing | 1 | 2017 | 24 | 0.040 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2017 | 118 | 0.040 |
Why?
|
| Models, Economic | 1 | 2017 | 101 | 0.040 |
Why?
|
| Cardiac Valve Annuloplasty | 1 | 2016 | 11 | 0.040 |
Why?
|
| Markov Chains | 1 | 2017 | 175 | 0.040 |
Why?
|
| North America | 1 | 2017 | 314 | 0.040 |
Why?
|
| United States | 2 | 2013 | 15433 | 0.040 |
Why?
|
| Radiologists | 1 | 2018 | 163 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 1183 | 0.030 |
Why?
|
| Affect | 1 | 2018 | 288 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2017 | 226 | 0.030 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2020 | 318 | 0.030 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2015 | 41 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2017 | 298 | 0.030 |
Why?
|
| Europe | 1 | 2017 | 649 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2018 | 527 | 0.030 |
Why?
|
| Social Support | 1 | 2018 | 560 | 0.030 |
Why?
|
| Polysomnography | 1 | 2015 | 155 | 0.030 |
Why?
|
| Emergencies | 1 | 2016 | 202 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2018 | 1544 | 0.030 |
Why?
|
| Prosthesis-Related Infections | 1 | 2017 | 232 | 0.030 |
Why?
|
| Decision Making | 1 | 2022 | 1287 | 0.030 |
Why?
|
| Ontario | 1 | 2014 | 98 | 0.030 |
Why?
|
| Premedication | 1 | 2014 | 135 | 0.030 |
Why?
|
| Arteries | 1 | 2015 | 274 | 0.030 |
Why?
|
| Emotions | 1 | 2018 | 562 | 0.030 |
Why?
|
| Wrist Injuries | 1 | 2013 | 12 | 0.030 |
Why?
|
| British Columbia | 1 | 2013 | 24 | 0.030 |
Why?
|
| Rosuvastatin Calcium | 1 | 2013 | 43 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2013 | 4938 | 0.030 |
Why?
|
| Fluorobenzenes | 1 | 2013 | 39 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 1323 | 0.030 |
Why?
|
| Reoperation | 1 | 2017 | 1382 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 2588 | 0.030 |
Why?
|
| Heptanoic Acids | 1 | 2013 | 96 | 0.030 |
Why?
|
| Simvastatin | 1 | 2013 | 106 | 0.030 |
Why?
|
| United Kingdom | 1 | 2013 | 257 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2014 | 323 | 0.030 |
Why?
|
| Hip Fractures | 1 | 2013 | 76 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 1148 | 0.030 |
Why?
|
| Reagent Strips | 1 | 2011 | 8 | 0.030 |
Why?
|
| Spinal Fractures | 1 | 2013 | 132 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2015 | 577 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2017 | 1529 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2013 | 756 | 0.020 |
Why?
|
| Urinalysis | 1 | 2011 | 84 | 0.020 |
Why?
|
| Multiple Organ Failure | 1 | 2012 | 177 | 0.020 |
Why?
|
| Thrombosis | 1 | 2017 | 781 | 0.020 |
Why?
|
| Hypercholesterolemia | 1 | 2013 | 259 | 0.020 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2016 | 563 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2011 | 224 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 2014 | 554 | 0.020 |
Why?
|
| Heart Rate | 1 | 2013 | 737 | 0.020 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2011 | 314 | 0.020 |
Why?
|
| Pyrroles | 1 | 2013 | 576 | 0.020 |
Why?
|
| Palliative Care | 1 | 2020 | 2037 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 4298 | 0.020 |
Why?
|
| Outpatients | 1 | 2011 | 462 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2009 | 203 | 0.020 |
Why?
|
| Peripheral Arterial Disease | 1 | 2011 | 267 | 0.020 |
Why?
|
| Patient Safety | 1 | 2013 | 649 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 2594 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 3472 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 2450 | 0.020 |
Why?
|
| Animals | 1 | 2009 | 59536 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 4758 | 0.010 |
Why?
|
| Sulfonamides | 1 | 2013 | 1823 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 8865 | 0.010 |
Why?
|
| Child | 1 | 2022 | 29154 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2013 | 3518 | 0.010 |
Why?
|